Dyslipidemia management in athletes: A comparative commentary on the 2026 ACC/AHA/Multisociety Guideline and contemporary sports cardiology recommendations.
- 1Sports Cardiology Program, Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abstract
Coronary artery disease (CAD) is the leading cause of exercise-related sudden cardiac death in athletes older than 35 years, and dyslipidemia is one of its principal modifiable drivers. The 2026 ACC/AHA/Multisociety Guideline on the Management of Blood Cholesterol introduces several advances directly relevant to athletes, including restored LDL-C treatment targets, universal lipoprotein(a) [Lp(a)] measurement, the PREVENT-ASCVD risk equations, expanded options for selective coronary artery calcium (CAC) scoring, and a more aggressive approach to lipid-lowering therapy (LLT). However, sports cardiology guidelines and consensus statements offer important caveats that must be reconciled with these general-population recommendations: existing risk calculators, including PREVENT, do not reliably estimate cardiovascular risk in athletes, and routine CAC scoring is not recommended in athletes at low calculated risk. This commentary compares and contrasts general-population dyslipidemia recommendations with athlete-specific guidance from contemporary sports cardiology consensus documents, highlights recent evidence on Lp(a), wearable-derived training load, and risk score performance across the physical activity spectrum, and proposes a five-step clinical framework, refined to reflect athlete-specific risk stratification, for dyslipidemia evaluation and management in this population.
Related
- Citation Fabrication and Accuracy in AI-Generated Psychiatric Research: A Comparative Evaluation of Four Contemporary Large Language Models
- Comparative midterm outcomes of contemporary revascularization strategies for acute lower limb ischemia: a retrospective cohort study
- Current Evidence, Diagnostic Challenges, and Contemporary Management of Lymphocytic Colitis: A Case Report and Literature Review
- Consensus recommendations for neurofibromatosis type 1 management in Asia Pacific
- AFSSAPS recommendations for the management of urinary tract infections in children
BibTeX
@article{garba2026dyslipidemia,
title = {{Dyslipidemia management in athletes: A comparative commentary on the 2026 ACC/AHA/Multisociety Guideline and contemporary sports cardiology recommendations.}},
author = {Deen L Garba and Sohail Zahid and Roger S Blumenthal and Lili A Barouch},
journal = {American journal of preventive cardiology},
year = {2026},
month = jul,
doi = {10.1016/j.ajpc.2026.101735},
url = {https://europepmc.org/article/MED/42997016},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Dyslipidemia management in athletes: A comparative commentary on the 2026 ACC/AHA/Multisociety Guideline and contemporary sports cardiology recommendations.
AU - Deen L Garba
AU - Sohail Zahid
AU - Roger S Blumenthal
AU - Lili A Barouch
PY - 2026
DA - 2026/07/04
JO - American journal of preventive cardiology
DO - 10.1016/j.ajpc.2026.101735
UR - https://europepmc.org/article/MED/42997016
AB - Coronary artery disease (CAD) is the leading cause of exercise-related sudden cardiac death in athletes older than 35 years, and dyslipidemia is one of its principal modifiable drivers. The 2026 ACC/AHA/Multisociety Guideline on the Management of Blood Cholesterol introduces several advances directly relevant to athletes, including restored LDL-C treatment targets, universal lipoprotein(a) [Lp(a)] measurement, the PREVENT-ASCVD risk equations, expanded options for selective coronary artery calcium (CAC) scoring, and a more aggressive approach to lipid-lowering therapy (LLT). However, sports cardiology guidelines and consensus statements offer important caveats that must be reconciled with these general-population recommendations: existing risk calculators, including PREVENT, do not reliably estimate cardiovascular risk in athletes, and routine CAC scoring is not recommended in athletes at low calculated risk. This commentary compares and contrasts general-population dyslipidemia recommendations with athlete-specific guidance from contemporary sports cardiology consensus documents, highlights recent evidence on Lp(a), wearable-derived training load, and risk score performance across the physical activity spectrum, and proposes a five-step clinical framework, refined to reflect athlete-specific risk stratification, for dyslipidemia evaluation and management in this population.
SN - 2666-6677
ER -